AOD-9604
Anti-Obesity Drug-9604
A modified fragment of human growth hormone (amino acids 176-191) designed to stimulate lipolysis without affecting blood sugar or tissue growth. Originally developed as an anti-obesity drug.
Typical Cost
$50-100/vial (5mg)
Status
Research
Peptide Profile
AOD-9604
Mechanism of Action
Mimics the fat-burning portion of HGH without the anabolic effects. Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor activation. Does not affect IGF-1 levels or glucose metabolism.
Common Dosages
subcutaneous
300mcg
Daily · 4-8 weeks
oral
5-10mg
Daily · 4-8 weeks
Benefits
Targeted fat loss
No blood sugar effects
No growth effects
Improved metabolism
Cartilage repair
Joint health
Side Effects
Injection site reactions
Headache
Fatigue
Nausea (rare)
Key Research
AOD-9604 in obesity treatment
Demonstrated significant reduction in body fat with minimal side effects in clinical trials
AOD-9604 and cartilage repair
Showed promising results for cartilage regeneration and joint health
Regulatory Status
FDA-approved for lipodystrophy in some contexts. Available by prescription in certain regions. Research status varies.
Contraindications
- ⚠Pregnancy/breastfeeding
- ⚠Active cancer
AOD-9604's targeted fat loss without metabolic disruption complements GLP-1 therapy. SeraVia Energy+ Boost may support the metabolic demands of combined protocols.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.